tiprankstipranks
Advertisement
Advertisement
PremiumCompany AnnouncementsXORTX to Voluntarily Delist from TSX Venture Exchange, Maintain Nasdaq Listing
2M ago
Premium
Company Announcements
XORTX Raises US$5 Million in Public Offering to Fund Kidney and Gout Drug Programs
3M ago
Premium
Company Announcements
XORTX files Q1 2026 unaudited results showing lower cash and equity
3M ago
Xortx Therapeutics meets Nasdaq continued listing requirements
PremiumThe FlyXortx Therapeutics meets Nasdaq continued listing requirements
4M ago
Premium
Company Announcements
XORTX Closes US$3 Million Acquisition of Vectus Kidney Anti‑Fibrotic Program
4M ago
Premium
Company Announcements
XORTX Closes US$3 Million Deal for Vectus Kidney Anti-Fibrotic Program
4M ago
PremiumCompany AnnouncementsXORTX Delays Effective Date of One-for-Five Share Consolidation
5M ago
Premium
Company Announcements
XORTX Consolidates Shares in Bid to Maintain Nasdaq Listing
5M ago
Premium
Company Announcements
XORTX Shareholders Approve Reverse Split to Preserve Nasdaq Listing
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100